Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cell-free DNA methylation pattern analysis refers to methods by which the methylation profile of circulating, fragmented DNA found in bodily fluids is assessed as a noninvasive biomarker for disease detection, tissue-of-origin identification, and monitoring of biological processes. cfDNA methylation patterns reflect their tissue or cellular origin due to cell-type-specific DNA methylation signatures. Analysis of these patterns is increasingly used for the diagnosis and monitoring of cancers, noninvasive prenatal testing, and in transplantation medicine. Technologies range from bisulfite sequencing and methylation-sensitive enzyme digestion to advanced fragmentomic assays (such as FRAGMA), which can predict methylation from DNA fragmentation profiles[1][2][3][4][5][6]. Although not a biological target amenable to drug interaction, cfDNA methylation profiling is a powerful bioanalytical tool for precision diagnostics. Its main challenges include technical issues such as DNA degradation during sample processing and limited specificity of some assays[4][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cell-free DNA methylation pattern analysis.